US87164F1057
US87164F1057
Syndax Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 172.352.000 | 23.680.000 | 627.8% |
| Cost of Revenue | 6.970.000 | 826.000 | 743.8% |
| Gross Profit | 165.382.000 | 22.854.000 | 623.6% |
| 438.466.000 | 362.526.000 | 20.9% | |
| Operating Income | -273.084.000 | -339.672.000 | 19.6% |
| Pretax Income | -285.422.000 | -318.758.000 | 10.5% |
| Net Income Common Stockholders | -285.422.000 | -318.758.000 | 10.5% |
| -- | -- | -- | |
| -- | -- | -- |